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Abstract
Background: Home management of malaria (HMM), promoting presumptive treatment of febrile children in the
community, is advocated to improve prompt appropriate treatment of malaria in Africa. The cost-effectiveness of HMM is
likely to vary widely in different settings and with the antimalarial drugs used. However, no data on the cost-effectiveness of
HMM programmes are available.
Methods/Principal Findings: A Markov model was constructed to estimate the cost-effectiveness of HMM as compared to
conventional care for febrile illnesses in children without HMM. The model was populated with data from Uganda, but is
designed to be interactive, allowing the user to adjust certain parameters, including the antimalarials distributed. The model
calculates the cost per disability adjusted life year averted and presents the incremental cost-effectiveness ratio compared
to a threshold value. Model output is stratified by level of malaria transmission and the probability that a child would receive
appropriate care from a health facility, to indicate the circumstances in which HMM is likely to be cost-effective. The model
output suggests that the cost-effectiveness of HMM varies with malaria transmission, the probability of appropriate care,
and the drug distributed. Where transmission is high and the probability of appropriate care is limited, HMM is likely to be
cost-effective from a provider perspective. Even with the most effective antimalarials, HMM remains an attractive
intervention only in areas of high malaria transmission and in medium transmission areas with a lower probability of
appropriate care. HMM is generally not cost-effective in low transmission areas, regardless of which antimalarial is
distributed. Considering the analysis from the societal perspective decreases the attractiveness of HMM.
Conclusion: Syndromic HMM for children with fever may be a useful strategy for higher transmission settings with limited
health care and diagnosis, but is not appropriate for all settings. HMM may need to be tailored to specific settings,
accounting for local malaria transmission intensity and availability of health services.
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Introduction
Prompt treatment with effective antimalarial drugs is one of the
key strategies for reducing the burden of malaria. However,
health-care infrastructure is often inadequate in Africa, limiting
availability of diagnostics and malaria treatment [1,2]. The World
Health Organization (WHO) has promoted home management of
malaria (HMM) as a major strategy to improve access to
antimalarials [3], and eighteen African countries have adopted
this policy [4]. HMM involves presumptively treating febrile
children at or near home with pre-packaged antimalarials
distributed by trained members of the community. The applica-
tion of HMM strategies varies somewhat in different settings. In
Uganda, volunteers from the community are trained to evaluate
and treat febrile children and are provided with antimalarial drugs
from the Ministry of Health to distribute free-of-charge. The
community drug distributors presumptively provide antimalarials
for treatment of febrile illnesses in young children, without
confirmation using a diagnostic test. Although HMM aims to
minimize barriers to care, there are potential downsides to this
strategy [5]. Presumptive treatment of all febrile illnesses as
malaria could result in poor health outcomes due to delays in
treating non-malarial illnesses [6], unnecessary exposure to
antimalarial medications and their toxicities [7], increased drug
pressure and potential for parasite resistance [8], and wastage of
valuable drugs reducing their cost-effectiveness [9]. In addition,
HMM is a major and costly undertaking, requiring considerable
investment [10], which may divert resources from other public
health activities.
Despite widespread advocacy for HMM, data supporting the
strategy are limited. The effectiveness and cost-effectiveness of
HMM have not been fully established in many settings. The few
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epidemiology, healthcare setting and drug resistance patterns, and
very few studies have evaluated use of artemisinin-based
combination therapies (ACTs) in HMM programmes [11].
Whether ACTs, which have been adopted as first-line treatment
for uncomplicated malaria in most African countries, can be
successfully incorporated into HMM and used safely and
effectively is a critical question [5,12].Two recent studies suggest
that introducing ACTs into HMM programmes is feasible and
acceptable, resulting in high utilization and increasing prompt
appropriate treatment [4,13]. However, currently there are no
published data on the cost-effectiveness of ACTs in HMM
programmes.
Uganda was the first country to adopt HMM launching the
national home-based management of fever programme in 2002
[14]. Uganda’s HMM programme appears to be welcomed by the
community, and has been shown to increase the proportion of
febrile children who receive prompt antimalarial treatment
[14,15,16,17,18]. The Ugandan Ministry of Health plans to
incorporate artemether-lumefantrine (AL), an ACT, into the
HMM program, but distribution of this regimen has been limited
by severe shortages of the drugs [19]. Deployment of ACTs within
the public health sector already poses significant challenges to
many countries [20,21], and the costs and benefits of deploying of
ACTs into HMM will need to be assessed.
HMM is likely to be most effective and cost-effective in areas
with high malaria transmission, limited health care infrastructure,
and poor access to antimalarial treatment. In a recent study
conducted in Kampala, the urban capital of Uganda, for instance,
provision of AL at home significantly improved the proportion of
febrile children receiving prompt effective antimalarial treatment
compared to conventional care, but only produced modest health
benefits at the cost of substantial over-treatment [22]. These results
suggest that HMM may not be appropriate for areas with lower
malaria transmission and better access to care. These findings,
however, are by no means generalizable to areas with different
malaria transmission intensity, or where access to health care
facilities might be more limited. Obtaining primary data from a
broad range of settings on the other hand is logistically impractical.
There is a need, therefore, for analytical tools to establish where
HMM is expected to be cost-effective. To investigate further the
cost-effectiveness of HMM in different settings, a Markov model
was developed as a decision support tool to compare the cost-
effectiveness of HMM to conventional care for febrile illnesses in
children under five. The model allows the user to adjust certain
input parameters, and produces output stratified by level of
malaria transmission and the probability that a child would receive
appropriate care from a health facility, indicating the circum-
stances in which HMM is likely to be cost-effective (Model S1).
Methods
Overview
The model is designed to compare the costs and health
outcomes for children under five with febrile illness who benefit
from an HMM programme to current conventional care for
children without HMM. This comparison is made across different
probability strata that a child will receive appropriate treatment
for malaria and bacterial illnesses from existing health services,
including correct diagnosis and effective treatment. This stratifi-
cation aims to capture the differences between, for instance, urban
areas where good quality health care might be available, and more
remote areas where access to health care is limited or in extreme
cases non-existent. For children in the HMM arm, all non-severe
febrile illnesses are treated presumptively with an antimalarial
regimen. If the antimalarial is ineffective in treating a true case of
malaria, or if the cause of illness is other than malaria, the illness
can become severe. In the conventional care group a proportion of
children will receive appropriate treatment according to the
probability of accessing high quality care. Children who access
good quality care are assumed to be correctly diagnosed as having
either malaria or non-malarial illness, and are assumed to receive
appropriate treatment. Children without access to health care are
assumed to go untreated and face a higher probability of
developing severe illness. For children that develop severe illness
in both arms, the mortality rates for the proportion of children
who cannot access good quality care will be higher than in those
with access to health services.
Model design
The Markov model defines thirteen mutually exclusive health
states representing childhood illness (Figure 1). Costs and health
outcomes were attached to each health state, and transition
probabilities were assigned to dictate the movement of children
between the states over discrete time periods, or cycles [23]. The
model was constructed using Microsoft Excel (2007) and macros
were written with Microsoft Visual BasicH 6.3. The model was
populated with data from Uganda, but is designed to be
interactive, allowing the user to adjust certain parameters,
including the drugs distributed in HMM and as first-line treatment
for uncomplicated malaria in health facilities, and the perspective
of the analysis. The transition probabilities and costs can also be
adjusted.
Markov states
The thirteen discrete health states included: State A: Suscep-
tible, in which a child is healthy, but susceptible to illness; State B:
Uncomplicated malaria; States C–E: Post-malaria weeks 2–4,
representing the weeks following treatment for malaria during
which a patient is at risk for recurrent malaria; State F: Severe
malaria; State G: Non-malaria febrile illness; States H–K:
Antimalarial prophylaxis weeks 1–4, representing the weeks
following an antimalarial treatment during which a patient could
benefit from a protective effect of the antimalarial; State L: Severe
bacterial illness; and State M: Death. The arrows in the diagram
represent the possible transitions that may occur between health
states from one cycle to the next. The circular arrows alongside
States A, B, and G indicate that a child may remain in the state s/
he was in during the previous cycle.
Transition probabilities
The probability of transitioning between each of the Markov
states was estimated from data available in the literature, or where
data were lacking, from expert opinion gathered in a Delphi
survey (Table 1). The probability of developing uncomplicated
malaria (State B) was determined from published estimates of the
annual malaria incidence in children under five, ranging from 0.1
to 8 per episodes per child per year [15,24]. The probability that a
child with uncomplicated malaria (State B), who was appropriately
treated, would develop severe malaria (State F), or die (State M),
was determined from primary data collected in Kisiizi hospital in
South West Uganda and from the literature [25,26]. The
probability that a child with uncomplicated malaria (State B),
who was inappropriately, inadequately, or not treated, would
develop severe malaria (State F), or die (State M), were determined
from a Delphi survey [27].
Assuming that a child with uncomplicated malaria was correctly
treated, the probability that they would transition through the
Economic Evaluation of HMM
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(State A), or be at risk of another episode of uncomplicated malaria
(State B) was based on the probability of malaria recurring due to
recrudescence as determined by the efficacy of the antimalarial
treatment, or re-infection, as determined by the level of malaria
transmission and the duration of the post-treatment prophylactic
effect of therapy. These probabilities were estimated using the
risk of parasitemia, unadjusted by genotyping, as measured in
antimalarial drug efficacy studies conducted in Uganda
[28,29,30,31,32,33,34].
The probability that a child would develop a non-malarial
febrile illness (State G) was based on estimates for the incidence of
febrile episodes per year [25], subtracting the incidence of malarial
episodes. The proportion of non-malaria febrile illnesses that
would require antibiotic treatment (30%) was determined from the
Delphi survey. The probabilities that a child with a non-malaria
febrile illness (State G) who was appropriately treated would
develop a severe bacterial illness (State L), or die (State M), were
estimated from expert opinion as used in previous publications
[35,36]. The probabilities that a child with a non-malarial illness
(State G) who did not receive appropriate antibiotic treatment
would develop a severe bacterial illness (State L), or die (State M),
were estimated from the Delphi survey.
The likelihood that a child with a non-malaria febrile illness
would acquire a new malaria infection was based on malaria
transmission intensity and the duration of the post-treatment
prophylactic effect of therapy. Those children who received an
antimalarial drug were assumed to be at lower risk due to the
benefits of post-treatment prophylaxis (States H–K). The potential
duration of post-treatment prophylaxis varied with the terminal
elimination half-life and efficacy of the drugs, and was limited to
four weeks in the model. Transition probabilities were estimated
from the risk of new infection, adjusted by genotyping, as
measured in antimalarial drug efficacy studies conducted in
Uganda [28,29,30,31,32].
Costing
The costs of Uganda’s HMM programme were obtained from
the Ministry of Health. The costs of purchasing and supplying
antimalarial drugs, and training and monitoring community drug
distributors (CDDs), were considered programme costs. In
Uganda, CDDs are unpaid volunteers; the opportunity cost to
their time was estimated from interviews with three CDDs. CDD
time was assigned a monetary value equivalent to the Ugandan
average wage [37].
The cost of providing good quality outpatient care was obtained
from a clinic run by an international non-governmental organi-
zation in eastern Uganda. Costs were obtained for construction,
overheads, and variable inputs, excluding the cost of providing
AL, the current first line treatment for malaria in Uganda, which is
included in the model separately. The costs of treating a child with
severe illness were estimated from a mid-sized hospital run by a
Figure 1. Illustration of the Markov model. Patients transition through the 13 states, each of which has its associated costs and health
outcomes. The arrows depict which transitions can occur from one cycle to the next. The transition probabilities differ between patients that receive
HMM and those who do not, and according to whether patients can access appropriate health care facilities.
doi:10.1371/journal.pone.0012439.g001
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using patient records for treatments received and labour costs for
staff, and step-down hospital costing were used to calculate
departmental expenditure and to estimate the proportion of their
services dedicated to pediatric care [38].
Household costs for management of febrile illness in children,
including user fees, travel expenses, drugs purchased and other
illness-related expenditures were obtained from the Kampala
HMM trial [22]. Indirect costs including productivity losses due to
the time caregivers spent away from their usual activities while
caring for a sick child were costed using the average wage for
unskilled workers [37]. Costs were collected in Ugandan Shillings
and converted to US dollars (1USD =1686 Uganda Shillings for
the year 2007). Costs were not discounted due to the relatively
short time horizon.
The model permits analysis from either the provider or societal
perspective. The provider perspective includes costs for HMM,
and the costs of providing outpatient and inpatient care. The
societal perspective includes provider costs, plus household costs
and an additional cost for the potential harm of unnecessary
antimalarial treatment. Such adverse consequences could include
drug toxicity, spread of drug resistance, and use of scarce
resources. The only available study to estimate this suggested that
the provision of 200 antimalarial treatments will eventually result
in the loss of one life in the future [39]. However, in our analysis a
more conservative estimate of one loss of life per 600 antimalarial
treatments was used as the potential harm of treatment, given that
use of scarce resources is already accounted for in the drug costs.
This value for the potential harm of treatment and most other
parameters can be modified by the user to explore the impact on
results.
Antimalarial drugs
The model allows the user to select the drugs to be distributed in
the HMM programme and those to be used as first-line treatment
for uncomplicated malaria at the health facilities. Options for both
include CQ+SP, amodiaquine + artesunate (AQ+AS), AL, and
dihydroartemisinin-piperquine (DP). The model also permits the
user to customize the characteristics of a regimen to be distributed
through either pathway.
Cost -effectiveness outcome
The model was designed to calculate the cost per disability
adjusted life year (DALY) averted. Life expectancy in Uganda was
estimated at 52 years, which was used to calculate the number of
years of life lost for each death [40], discounted at 3% [41].
Disability weights were assigned according to the Global Burden
of Disease weightings (0.21 for non-severe illness, 0.47 for severe
illness, and 1 for death) [42], and were used to calculate the
number of DALYs in each arm. A decision threshold equivalent to
the 2007 Ugandan GDP per capita ($360) was used to determine
when an intervention might be considered cost-effective [43,44].
The model allows the user to adjust the decision threshold,
including options of $25, $150, $360, and $720.
Model output
A hypothetical cohort of 1000 children was run through the
model using one-week cycles over five years. The model was
constructed using the assumption that all individuals entered the
model at time 0 in a healthy state. During each cycle, the
transition probabilities were applied, and the distribution of
patients in each of the health states was adjusted [23]. The costs
and disability weights assigned to each health state are aggregated
Table 1. Parameter values.
Costs Estimate Source
HMM distribution $0.2 per child/month Primary data, Uganda MoH documents
OPD care (excluding drugs) $4.5 per visit Primary data – Jinja clinic
Inpatient care for severe malaria $20 per stay (Based on average length of stay) Primary data- Kisiizi Hospital
Inpatient care for non-malaria severe illness $12 per stay (Based on average length of stay) Primary data- Kisiizi Hospital
Antimalarial costs HOMAPAK - $0.15 per febrile episode;
AL - $0.65 per dose
Uganda MoH
Antibiotic costs $0.3 per dose [35]
Transition probabilities
Transmission Low High
Untreated malaria becoming severe 30% (10258%) 13% (7230%) Delphi survey results for low and high transmission
intensities [27]. In brackets are the inter-quartile ranges used
in the sensitivity analyses. The medium transmission values
in the model were an average of the high and low ones.
CFR untreated severe malaria 75% (50285%) 60% (45280%)
Proportion of NMFI that require antibiotics 30% (10240%)
Untreated bacterial NMFI becomes severe 40% (18273%)
CFR untreated severe NMFI 50% (28268%)
Disability adjusted life year (DALY) related parameters
Life expectancy 52 years [40]
Disability weights Non severe
illness
Severe illness Death Global Burden of Disease disability weightings
0.21 0.47 1
Discount rate 3% [41]
doi:10.1371/journal.pone.0012439.t001
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in each state.
The results of the analysis are presented across different levels of
malaria transmission, stratified as low, medium, or high defined as
an incidence of malaria episodes of 0.1 malaria cases a year in low
transmission areas, 4 cases a year in medium transmission, and 8
cases in high transmission areas [45,46,47,48,49]. Results are also
stratified by the probability that a child would receive appropriate
medical care from a health facility, arbitrarily categorized as 0%,
25%, 50%, and 100% (Figure 2). This probability determined the
proportion of children in the cohort that cycled through the model
according to the transition probabilities for patients receiving
appropriate treatment, while the remainder of the cohort is
assumed to receive inadequate or no treatment, with their own
transition probabilities (characterised by worse health outcomes).
The final outcome of the model is a product of the incremental
cost-effectiveness ratio (ICER), and the ceiling ratio (the threshold
value decision-makers are willing to pay to avert a DALY [43]), set
at US$360 in this analysis [50]. Rather than presenting ICERs
numerically, the results are categorized in manner to help guide
policy-makers [37]:
N Outcome 1. HMM dominates, i.e. it is more effective and less
costly (labelled DTS)
N Outcome 2. HMM is more effective but more costly, and the
ICER is lower than the ceiling ratio suggesting the intervention
is cost-effective (labelled C/E)
N Outcome 3. HMM is more effective, but more costly, however
the ICER is higher than the ceiling ratio suggesting the
intervention is not cost-effective (labelled Not C/E)
N Outcome 4. HMM is less costly but less effective (labelled
LCLE)
N Outcome 5. HMM is dominated, i.e. it is less effective and
more costly (Labelled DTD)
From a policy-maker’s perspective, Outcomes 1 and 2 would
unequivocally justify the adoption of the intervention, subject to
budget availability. Outcome 3 suggests that although HMM is
more effective, resources would be better used elsewhere.
Outcome 4 indicates HMM is less effective, suggesting that the
intervention should be rejected, even if it is less expensive, unless
implementing such an intervention results in economic gains that
outweigh the strong ethical objections to introducing a less
effective intervention. Outcome 5 would suggest that HMM
should be unequivocally rejected.
Sensitivity analysis
The robustness of the results to variation in the input variables
was assessed using sensitivity analyses. The impact of using
different antimalarials in the HMM programme and at health
facilities was also explored, including use of a hypothetical ‘ideal’
antimalarial, which was assumed to be inexpensive (cost equivalent
to chloroquine), and 100% effective, providing post-treatment
prophylaxis for 4 weeks. The model was initially run from the
provider’s perspective. In the sensitivity analysis, the societal
perspective, including costs for carers, providers, and the harm of
treatment factor, was used. Sensitivity analyses were also carried
out for the values obtained in the Delphi survey using inter-
quartile ranges for outcomes of untreated malaria, the proportion
of non-malarial febrile illness that would benefit from antibiotic
treatment, and the health outcomes for such illnesses if untreated
[27].
Results
Costing
In Uganda’s HMM programme, the drug costs constitute the
majority of the overall programme costs, regardless of the regimen
(Table 2). Replacing CQ+SP with AL increases the drug costs and
total cost per child considerably. The average cost for providing
high quality outpatient care was $4.5 per patient visit. Inpatient
care costs of treating severe illnesses were estimated to be $11.2 per
hospital stay for malaria and $20.4 per stay for non-malaria
illnesses. Treatment for malaria tended to be less expensive due to
shorter duration of hospitalization and lower costs of antimalarial
drugs relative to the treatments provided other patients. The
household costs of treating febrile episodes were lower with HMM
programme, compared to conventional care (no HMM), averaging
$0.90 and $1.50, respectively. The amount of time caregivers spent
away from their usual activities while their child was ill was slightly
lower with an HMM programme (0.85 days) than without (0.96
Figure 2. The model interface. The lower panel is the model output indicating the circumstances in which HMM is likely to be appropriate. Above
this are the controls where the user can adjust the costs and transition probabilities, select drugs for both HMM and health facilities, determine the
perspective for the analysis, and set the decision threshold.
doi:10.1371/journal.pone.0012439.g002
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household costs per episode of childhood fever were $1.90 with
HMM and $2.80 without.
HMM distributing CQ+SP
In the baseline analysis, CQ+SP was selected for HMM, and
AL was selected for first-line treatment for uncomplicated malaria
at the health facilities. The model output chart (Figure 3) indicates
that the cost-effectiveness of HMM using CQ+SP from the
provider perspective varies with malaria transmission and the
probability that a child would receive appropriate care. HMM is
most attractive in medium to high malaria transmission settings,
where the probability of appropriate care is limited, as evidenced
by the placement of Outcomes 1 and 2 on the figure. In low
transmission areas, HMM is only more effective than the
alternative if the probability of appropriate care is zero; however,
here the HMM intervention is more costly, and the ICER is
higher than the ceiling ratio therefore it is not deemed cost-
effective (Outcome 3). HMM is less costly but less effective
(Outcome 4) than the alternative in low transmission settings if the
probability of appropriate care is 25% or greater, and in medium
to high transmission if that probability is 50% or above.
HMM distributing AL
Replacing CQ+SP with AL in HMM changes the output of the
model considerably (Figure 4). With AL, HMM becomes attractive
from the provider perspective in several areas where it was previously
lesseffective than the alternative.In high transmission areas,HMMis
moreeffectiveand lesscostly(Outcome1)inallsettings,exceptwhere
the probability of appropriate care is zero; here HMM is more costly,
but remains more effective (Outcome 2). In medium transmission
settings, HMM with AL is more effective (Outcomes 1 and 2) if the
probability of appropriate care is 50% or less, only becoming less
effective (Outcome 4) when the probability of access to appropriate
care is 100%. With AL, HMM remains more costly, but becomes
moreeffective (Outcome2) in low transmission settings where thereis
no chance of appropriate care. Even with AL, HMM is less effective
than the alternative in low transmission settings if the probability of
appropriate care is 25% or greater.
Sensitivity analysis
When a hypothetical ‘ideal’ antimalarial regimen was intro-
duced into HMM, with AL as the first-line treatment distributed at
health facilities, the output of the model changed little from the
provider perspective (Figure 5). Only in the medium transmission
setting where the probability of appropriate care was 100% did the
HMM intervention change from less effective (Outcome 4) to
more effective and highly attractive (Outcome 1). Otherwise, the
ICER output categories remained similar to those for HMM with
AL (Figure 4). When the model was run from the societal
perspective, including costs to the household and the potential
harm of unnecessary antimalarial treatment, HMM with AL
became unattractive in several areas (Figure 6). Where the
probability of appropriate care was over 50%, HMM became
Table 2. Costing results.
CQ+SP AL
Monthly cost per child Annual cost per child Monthly cost per child Annual cost per child
Staff (CDDs) $0.05 $0.60 (24%) $0.05 $0.60 (7%)
Provider cost (MoH) $0.05 $0.12 (5%) $0.05 $0.12 (1%)
Drugs $0.01 $1.80 (71%) $0.65 $7.80 (92%)
TOTAL $0.21 $2.52 $0.71 $8.52
doi:10.1371/journal.pone.0012439.t002
Figure 3. Model output for the Uganda HMM programme using CQ+SP from a provider perspective. The model suggests that HMM will
only be efficient in areas of medium and high transmission, where the probability of appropriate care is low. In low transmission areas HMM is more
effective but too costly, and is not cost-effective. CQ+SP = chloroquine + sulfadoxine-pyrimethamine.
doi:10.1371/journal.pone.0012439.g003
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transmission intensity. In low transmission settings where the
probability of appropriate care was zero, HMM went from more
effective (Outcome 2) to not effective (Outcome 5). Using estimates
for better and worse health outcomes for untreated malaria
according to the inter-quartile ranges in the Delphi survey had no
effect on the model outcome. Reducing the proportion of NMFIs
that require antibiotics and the probability that these result in
death when untreated, improved the cost-effectiveness of HMM
greatly, as shown in Figure 7. Using higher estimates for the
proportion of NMFIs that require antibiotics and the probability of
death for untreated NMFIs did not have a significant effect.
Discussion
A Markov model was constructed as a decision support tool to
estimate the cost-effectiveness of HMM as compared to conven-
tional care for febrile illnesses in children in Uganda. The analysis
indicates that the cost-effectiveness of HMM varies with malaria
transmission and the probability that a child will receive
appropriate care from a health facility. Where transmission is
high and the probability of appropriate care is limited, HMM is
likely to be cost-effective from a provider perspective. Replacing
CQ+SP with AL in HMM expands the range of beneficial
coverage, but HMM only remains a highly attractive intervention
in areas of high malaria transmission, and in medium transmission
areas with a lower probability of appropriate care. Considering the
analysis from the societal perspective decreases the attractiveness
of HMM with AL. HMM is generally not cost-effective in low
transmission areas, regardless of which antimalarial is distributed.
HMM may be a useful strategy for higher transmission settings
with limited health care infrastructure, allowing carers to obtain
effective antimalarials without having to transport their children to
far away facilities, but is not appropriate for all settings.
Figure 4. Model output for the Uganda HMM programme using AL from a provider perspective. Introducing AL into HMM appears to be
efficient in most medium to high transmission areas, unless the probability that a child will receive appropriate care from a health facility is 100%. AL
= artemether-lumefantrine.
doi:10.1371/journal.pone.0012439.g004
Figure 5. Model output for the Uganda HMM programme using a hypothetical ‘ideal’ antimalarial from a provider perspective.
These results indicate that even if an ‘ideal’ antimalarial is introduced into HMM, the settings where HMM is cost-effective remain limited to medium
and high transmission areas, unless the probability of receiving appropriate care is zero.
doi:10.1371/journal.pone.0012439.g005
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treatment of malaria [17,51,52]. Expanding programmes to
provide more comprehensive care, including treatment for
respiratory illnesses and diarrhea has been suggested. In Uganda,
there are plans to integrate HMM into a programme of integrated
community case management (iCCM), in which village health
teams (VHTs) will provide presumptive treatment for malaria,
pneumonia, and diarrhea based on clinical criteria. iCCM
addresses the issue that not all fevers are due to malaria, and is
promoted by WHO [53,54]. However, this broader programme
still relies on presumptive treatment, and evidence supporting the
health impact, feasibility, and sustainability of iCCM are lacking.
The introduction of rapid diagnostic tests (RDTs) for malaria into
these programmes could enhance their effectiveness and improve
the targeting of both antimalarials and antibiotics.
There is increasing evidence that malaria transmission and the
burden of disease is decreasing in many areas of Africa
[55,56,57,58,59]. Although the reasons for this change are
multi-factorial and not always clear, there is optimism that the
trend will continue in at least a significant part of malaria-affected
Africa. Where malaria transmission is reduced, and the proportion
of febrile illnesses that are attributable to other illnesses increases,
this study demonstrates the strategy of presumptive treatment of all
fever cases for malaria becomes much less attractive. Indeed, the
World Health Organization has recently released new guidelines
regarding treatment of malaria, now recommending that suspect-
ed cases of malaria be confirmed by a parasitological test, when
possible [60]. The move towards universal diagnostic testing is a
major shift in malaria case management. Introduction of RDTs
for malaria into lower level health facilities and at the community-
level is currently being explored to expand diagnostic capability;
however, whether RDTs can be successfully utilized in the
periphery remains unclear [61].
The Markov model used in this analysis has several limitations.
Although the health states and transitions were designed to mimic
real scenarios, the model remains artificial and has to make
Figure 6. Model output for the Uganda HMM programme using AL from a societal perspective. Under this scenario HMM is only
warranted in medium to high transmission areas and where the probability of appropriate care is low.
doi:10.1371/journal.pone.0012439.g006
Figure 7. Model output for the Uganda HMM programme using AL in the context of a lower burden of non-malaria febrile illnesses.
When the proportion of non-malaria febrile illnesses are assumed to require less antibiotics and their health outcomes is estimates as less severe
HMM appears more beneficial in almost all areas.
doi:10.1371/journal.pone.0012439.g007
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were restricted to limit the complexity of the model. The model
did not account for the acquisition of antimalarial immunity in
children under five, which may occur early in high transmission
areas [62]; this would if anything reduce the effectiveness of
HMM. The model assumed that all children would be at equal risk
of acquiring malaria, regardless of age, which is an oversimplifi-
cation in high-transmission settings, but is difficult to quantify.
Immunity in older children would imply that HMM is a less
effective strategy for these children, as many of those with severe
symptoms are likely to have other, non-malarial causes of illness.
Neurological sequelae following episodes of severe malaria were
not accounted for, as including this consequence in the model
complicated it considerably and had negligible impact on
outcomes. Deaths from unrelated causes were also excluded as
these were assumed to be constant with or without HMM. The
probability that a child would receive appropriate medical care
from a health facility was also oversimplified in the model and the
stratification was arbitrary. Similarly, a different stratification of
the levels of access to care and the transmission intensity would
result in slightly different outcomes, however the overall message,
that HMM becomes a less cost-effective strategy as access to care
improves and transmission decreases, remains the same. A more
precise assessment of the cost-effectiveness of HMM in different
settings would require additional information about the different
steps of the pathway to appropriate care, including availability of
health services and malaria diagnostics, utilization, and quality of
care. The potential harm of unnecessary antimalarial treatment
including the risks of drug toxicity, spread of drug resistance, and
misuse of scarce resources, included in the societal costs, is very
challenging to value. Although consideration of these adverse
consequences is essential when weighing the benefits and risks of
HMM, significant uncertainty exists around this parameter, and
further research is needed to provide more accurate estimates.
These potential weaknesses are however unlikely to affect the key
outcomes of the model.
Conclusions
HMM programmes are being implemented across Africa, but
evidence of their cost-effectiveness is limited. This analysis suggests
that the cost-effectiveness of HMM varies substantially with
malaria transmission intensity and the probability that a child will
receive appropriate care at a health facility. Results of the model
suggest that adopting a policy of HMM with AL is justified from
the provider perspective in high transmission areas, regardless of
access to care; in most medium transmission areas, unless the
probability of appropriate care is 100%; and in low transmission
areas only if there is no chance of appropriate care. The analysis
suggests that HMM should not be adopted for use in other
settings, where the programme might be less effective and/or more
costly. Comprehensive implementation of HMM could result in
poor health outcomes and misallocate valuable resources. HMM
and other community-based strategies may need to be tailored to
specific settings, accounting for local malaria transmission intensity
and availability of health services.
Supporting Information
Model S1 Interactive model for the evaluation of HMM
strategies. The model is a Microsoft Excel file and requires that
macros are allowed to run.
Found at: doi:10.1371/journal.pone.0012439.s001 (0.57 MB
XLS)
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